Alnylam Pharma (ALNY) Tops Q4 EPS by 6c, Misses on Revenue; Offers FY26 Revenue Guidance
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $293.52 +0.74%
EPS Growth %: +409.4%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
DTGI, OCCI, MAYS, More
EPS Growth %: +409.4%
Financial Fact:
Research and development: 83.17M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of $1.25, $0.06 better than the analyst estimate of $1.19. Revenue for the quarter came in at $1.1 billion versus the consensus estimate of $1.15 billion.
GUIDANCE:
Alnylam Pharma sees FY2026 revenue of $4.9-5.3 billion, versus the consensus of $5.55 billion.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- Alloy (ALOY) files mixed shelf
- Comcast may build data centers, NBCUniversal may enter video game business - Reuters
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
